Pacific Edge says US medical and legal tides have turned in its favour

Pacific Edge says US medical and legal tides have turned in its favour
Pacific Edge chief executive Peter Meintjes. (Image: Pacific Edge)
Greg Hurrell
Pacific Edge is confident its newly announced $20 million capital raise, combined with new research results and professional validation, will keep it in the bladder cancer testing game.Chief executive Peter Meintjes says a clinical endorsement from the American Urological Association (AUA) should give it the medical and legal clout to regain Medicare coverage for its bladder cancer tests in the US.The dual NZX and ASX-listed medical technology company reported a net loss of $29.9m in the 12 months to March 31, 2025, compared with $29.5m in the...

More Markets

Vulcan Steel leads as reporting season approaches
Markets Market Close

Vulcan Steel leads as reporting season approaches

The S&P/NZX 50 Index closed 55.30 points higher at 12,889.38.

Jamie Gray 15 Aug 2025
Competition law changing to allow 'beneficial collaboration'
Markets

Competition law changing to allow 'beneficial collaboration'

Confidential submissions to the Commerce Commission will get a 10-year OIA exemption.

Pattrick Smellie 15 Aug 2025
Small cap spotlight: Blackpearl Group
Markets Small Cap Wrap

Small cap spotlight: Blackpearl Group

Founder Nick Lissette says it's patriotic to be listed, but hard work.

NZ sharemarket rises, Vista Group shares fall
Markets Market Close

NZ sharemarket rises, Vista Group shares fall

The New Zealand sharemarket was up on Thursday as most stocks on the main board lifted.

Tom Raynel 14 Aug 2025